Management of hematocrit levels for testosterone replacement patients, a narrative review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing literature without systematic search methodology or quantitative pooling
PubMed 40126900 · doi:10.1093/sxmrev/qeaf013
What was done
The authors conducted a narrative literature review searching PubMed and Google Scholar from 2000 to 2024 to evaluate the effects of testosterone replacement therapy on hematocrit and hemoglobin levels, associated cardiovascular risks, and strategies to manage erythrocytosis across different testosterone formulations.
What was found
The abstract reports no numerical values, effect sizes, or study counts. It notes that the literature on testosterone-induced hematocrit increases is conflicting, with some studies showing noninferior outcomes compared to placebo and others showing adverse cardiovascular effects. The extent of hematocrit increase depends on the route of administration, and erythropoiesis may benefit hypogonadal patients with anemia.
Why it matters
Elevated hematocrit is a primary reason clinicians discontinue testosterone therapy; understanding formulation-specific effects allows tailoring administration methods to avoid symptom relapse from treatment cessation.
Limits
As a narrative review, it lacks systematic search criteria, formal quality assessment, and quantitative synthesis. The abstract provides no sample sizes, specific hematocrit thresholds, or numerical comparisons between different testosterone delivery formulations.
Cited by
- supports Approximately 25% of men on testosterone replacement therapy develop elevated hematocrit or polycythemia.